Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine
Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced as part of the Research Agreement signed in May 2020 with Baylor College of Medicine and Texas Children’s Center for Vaccine Development, that Mymetics has piloted and successfully produced different virosome formulations which incorporate the SARS-CoV-2 recombinant protein. The Company has now shipped these formulations to Baylor College of Medicine where they will be tested and compared in a pre-defined preclinical model in accordance with the Research Agreement signed between the parties in May 2020. Results are expected in three months.
Since the end of April, Mymetics has started a project for the rapid development of a Covid-19 virosome-based vaccine and is partnering with leading academic institutions to explore and select the best SARS-CoVantigens,which could not only be efficacious in protecting against Covid-19 butarealso safe, easy to administer and dose sparing.Additional preclinical studies at other sites will be announced in the coming weeks.
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline, among which are the HIV-1/AIDS, intra-nasal Influenzaandmalaria,and collaborative projects in the field of allergy immunotherapy and in oncology.
Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing onboththe mucosal and serum immune response.
For further information, please visit www.mymetics.com.
Source: Mymetics (Press release)